Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site

Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress

(2020) Xiaoli Hu et al.   Cancer Cell International

iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition

(2019) Shuo Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

(2018) Qiang Zhang et al.   Cell Death & Disease

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Census and evaluation of p53 target genes

(2017) M Fischer   ONCOGENE

MolProbity: More and better reference data for improved all-atom structure validation

(2017) Christopher J. Williams et al.   PROTEIN SCIENCE

The synergistic antitumor effect of arsenic trioxide combined with cytotoxic T cells in pulmonary metastasis model of colon cancer

(2017) Lei Wang et al.   Oncotarget

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

(2016) Andreas C. Joerger et al.   Annual Review of Biochemistry

Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma

(2015) Hui Wang et al.   CANCER

Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase

(2014) Wensheng Yan et al.   PLoS One

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP

(2013) Min Lu et al.   CANCER CELL

Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial

(2013) Hong-Hu Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Allele-Specific p53 Mutant Reactivation

(2012) Xin Yu et al.   CANCER CELL

CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

(2012) W. C. Reinhold et al.   CANCER RESEARCH

Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells

(2012) R Wang et al.   LEUKEMIA

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition

(2012) R. Wilcken et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural and Functional Studies of LRP6 Ectodomain Reveal a Platform for Wnt Signaling

(2011) Shuo Chen et al.   DEVELOPMENTAL CELL

An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity

(2011) Tom J Petty et al.   EMBO JOURNAL

Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression

(2011) Wensheng Yan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

XDS

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

The Tumor Suppressor p53: From Structures to Drug Discovery

(2010) A. C. Joerger et al.   Cold Spring Harbor Perspectives in Biology

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

(2009) J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

Structural Biology of the Tumor Suppressor p53

(2008) Andreas C. Joerger et al.   Annual Review of Biochemistry

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

Structural Basis of Restoring Sequence-Specific DNA Binding and Transactivation to Mutant p53 by Suppressor Mutations

(2008) Oded Suad et al.   JOURNAL OF MOLECULAR BIOLOGY

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

(2008) F. M. Boeckler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA